These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 32215701)

  • 1. A randomized controlled trial comparing oral and intravenous iron supplementation after Roux-en-Y gastric bypass surgery.
    Schijns W; Boerboom A; de Bruyn Kops M; de Raaff C; van Wagensveld B; Berends FJ; Janssen IMC; van Laarhoven CJHM; de Boer H; Aarts EO
    Clin Nutr; 2020 Dec; 39(12):3779-3785. PubMed ID: 32402684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents.
    Abdel-Razeq H; Saadeh SS; Malhis R; Yasser S; Abdulelah H; Eljaber R; Kleib A; Ismael R
    Ther Adv Med Oncol; 2020; 12():1758835920953292. PubMed ID: 32952616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia.
    Kassianides X; Hazara AM; Macdougall IC; Kalra PA; Bhandari S
    Kidney Int Rep; 2022 Feb; 7(2):322-326. PubMed ID: 35155871
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review.
    Kassianides X; Bhandari S
    Drugs Context; 2021; 10():. PubMed ID: 33519940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron deficiency in heart failure.
    Dinatolo E; Dasseni N; Metra M; Lombardi C; von Haehling S
    J Cardiovasc Med (Hagerstown); 2018 Dec; 19(12):706-716. PubMed ID: 30222663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.
    Brandenburg V; Heine GH; Marx N; Stöhr R
    Clin Res Cardiol; 2020 Oct; 109(10):1316-1318. PubMed ID: 32215701
    [No Abstract]   [Full Text] [Related]  

  • 8. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
    Amarnani R; Travis S; Javaid MK
    Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure.
    Osman M; Syed M; Balla S; Kheiri B; Faisaluddin M; Bianco C
    Am J Cardiol; 2021 Feb; 141():152-153. PubMed ID: 33259800
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulatory factors associated with function and prognosis in patients with severe heart failure.
    Rullman E; Melin M; Mandić M; Gonon A; Fernandez-Gonzalo R; Gustafsson T
    Clin Res Cardiol; 2020 Jun; 109(6):655-672. PubMed ID: 31562542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart rate, mortality, and the relation with clinical and subclinical cardiovascular diseases: results from the Gutenberg Health Study.
    Münzel T; Hahad O; Gori T; Hollmann S; Arnold N; Prochaska JH; Schulz A; Beutel M; Pfeiffer N; Schmidtmann I; Lackner KJ; Keaney JF; Wild PS
    Clin Res Cardiol; 2019 Dec; 108(12):1313-1323. PubMed ID: 30953178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma FGF23 does not rise during physical exercise as a physiological model of sympathetic activation.
    Emrich IE; Baier M; Zawada AM; Meyer T; Fliser D; Scharhag J; Heine GH
    Clin Res Cardiol; 2019 Mar; 108(3):341-343. PubMed ID: 30091082
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.